Effects of uremic plasma on alpha- and beta-adrenoceptor subtypes. 1998

A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
Institute of Pharmacology and Toxicology, Martin Luther University of Halle-Wittenberg, Halle, Germany.

Responsiveness of adrenergic receptors is decreased in patients on maintenance hemodialysis. In this study we investigated whether uremic plasma might affect adrenergic receptors. For this purpose we determined the effects of uremic plasma obtained from 10 patients on hemodialysis treatment (mean age 61 +/- 3 years, dialysis frequency 3 x 4 h/week, duration of treatment 3 +/- 1 years) before and at the end of the 4-hour dialysis treatment on binding of radioligands to beta1- and beta2- as well as alpha1- and alpha2-adrenoceptors. Plasma from 6 healthy volunteers served as control; the plasmas were studied in three dilutions: undiluted, 1:1 (v/v) and 1:4 (v/v) with saline diluted. Plasma from healthy control did not significantly affect the number of beta1- and beta2- or alpha1- and alpha2-adrenoceptors. On the other hand, uremic plasma significantly decreased the number of beta1- and beta2-adrenoceptors; this inhibitory effect was also observed when plasma obtained at the end of the 4-hour dialysis treatment was investigated. On the other hand, uremic plasma did not significantly decrease the number of alpha1- and alpha2-adrenoceptors. We conclude that in patients on maintenance hemodialysis, the presence of inhibitory substance(s) in uremic plasma could be - at least partly - responsible for the beta-adrenoceptor hyporesponsiveness; the mechanism leading ot alpha-adrenoceptor hyporesponsiveness, however, remains to be elucidated.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009215 Myometrium The smooth muscle coat of the uterus, which forms the main mass of the organ. Uterine Muscle,Muscle, Uterine,Muscles, Uterine,Uterine Muscles
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays

Related Publications

A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
July 2010, Planta medica,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
September 2001, Pharmacological research,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
February 1982, The Journal of pharmacy and pharmacology,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
March 2005, Burns : journal of the International Society for Burn Injuries,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
March 1983, Archives internationales de pharmacodynamie et de therapie,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
October 1994, Sheng li xue bao : [Acta physiologica Sinica],
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
January 1997, The Journal of pharmacology and experimental therapeutics,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
December 2002, Vascular pharmacology,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
March 1996, The Journal of endocrinology,
A Ferchland, and O Rettkowski, and K Pönicke, and H J Deuber, and B Osten, and O E Brodde
July 1995, Naunyn-Schmiedeberg's archives of pharmacology,
Copied contents to your clipboard!